Ergoteles’s Achilles Therapeutics ACHL Stock Holding History

Ergoteles’s Portfolio ACHL Stock Details ACHL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-22,004	Closed	-$19.8K	–	1847
2022 Q4	$19.8K	Buy	+22,004	New	+$37K	﹤0.01%	1345

Other funds holding ACHL

Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Axa Paris, France $256M AUM 25.01% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Forefront Analytics West Conshohocken, Pennsylvania $110M AUM 18.54% 1-Year Est. Return

Ergoteles's ACHL Position: Q1 2023 in Review

Ergoteles sold out of Achilles Therapeutics (ACHL) in Q1 2023, closing a stake of 22,004 shares — an estimated $19.8K sold.

Ergoteles first reported a position in ACHL in Q4 2022 and held it in 1 quarter. The position peaked at $19.8K in Q4 2022. 18 funds tracked by Wall St. Rank hold ACHL as of Q1 2023.

Ergoteles reported no remaining Achilles Therapeutics position as of Q1 2023 after selling out during the quarter.
Ergoteles sold 22,004 Achilles Therapeutics shares in Q1 2023, an estimated $19.8K.
Ergoteles first reported a position in Achilles Therapeutics in Q4 2022 and held it in 1 quarter.
Ergoteles's Achilles Therapeutics position peaked at $19.8K in Q4 2022.
18 funds tracked by Wall St. Rank held Achilles Therapeutics as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.